Costs ris­ing, As­traZeneca switch­es con­trac­tors and once again de­lays sched­uled com­ple­tion of its trou­bled $650M-plus HQ project

Those ru­mors about big trou­ble for As­traZeneca’s $650 mil­lion (plus) HQ project proved to be en­tire­ly ac­cu­rate. To­day a spokesper­son for the phar­ma gi­ant tells me that they are switch­ing build­ing con­trac­tors and once again sig­nif­i­cant­ly de­lay­ing a planned move-in at the Cam­bridge, UK site. And the price tag for com­ple­tion is head­ed high­er.

Their state­ment in re­sponse to a query:

Yes, as the sci­en­tif­ic fit-out and com­mis­sion­ing phase of the build­ing takes shape, we are tran­si­tion­ing from Skan­s­ka to a com­pa­ny called Mace which has ex­per­tise in this next phase. As we be­gin this sci­en­tif­ic fit-out we will have more up­dates but, as of now, we’re look­ing at oc­cu­pa­tion in first half of 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER